ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 278 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,201,816 | -37.4% | 528,538 | -17.0% | 0.00% | 0.0% |
| Q2 2023 | $22,694,667 | +36.2% | 636,418 | -3.0% | 0.00% | 0.0% |
| Q1 2023 | $16,661,993 | -6.2% | 655,984 | +49.8% | 0.00% | -20.0% |
| Q4 2022 | $17,763,860 | +7.0% | 437,965 | -12.8% | 0.01% | +25.0% |
| Q3 2022 | $16,607,000 | +2.3% | 502,466 | +9.0% | 0.00% | 0.0% |
| Q2 2022 | $16,232,000 | -28.6% | 460,983 | -6.7% | 0.00% | -20.0% |
| Q1 2022 | $22,724,000 | -76.6% | 494,118 | -66.2% | 0.01% | +25.0% |
| Q4 2021 | $97,066,000 | +95.3% | 1,464,038 | +83.9% | 0.00% | -33.3% |
| Q3 2021 | $49,694,000 | -21.5% | 795,992 | +4.1% | 0.01% | -33.3% |
| Q2 2021 | $63,326,000 | +24.0% | 764,632 | -0.8% | 0.01% | +12.5% |
| Q1 2021 | $51,089,000 | -68.0% | 770,448 | -63.0% | 0.01% | -33.3% |
| Q4 2020 | $159,688,000 | +248.0% | 2,081,172 | +95.3% | 0.01% | +33.3% |
| Q3 2020 | $45,888,000 | -15.6% | 1,065,684 | -15.3% | 0.01% | -35.7% |
| Q2 2020 | $54,342,000 | +72.5% | 1,258,198 | +14.9% | 0.01% | +40.0% |
| Q1 2020 | $31,509,000 | -58.0% | 1,095,210 | -7.3% | 0.01% | -54.5% |
| Q4 2019 | $74,942,000 | +230.7% | 1,181,482 | +46.9% | 0.02% | +214.3% |
| Q3 2019 | $22,664,000 | -64.1% | 804,233 | -66.2% | 0.01% | 0.0% |
| Q2 2019 | $63,081,000 | +355.9% | 2,380,434 | +215.7% | 0.01% | 0.0% |
| Q1 2019 | $13,836,000 | +101.3% | 754,038 | +36.3% | 0.01% | +133.3% |
| Q4 2018 | $6,872,000 | -50.7% | 553,244 | -23.9% | 0.00% | -25.0% |
| Q3 2018 | $13,940,000 | +59.9% | 727,200 | +13.5% | 0.00% | +33.3% |
| Q2 2018 | $8,716,000 | +118.7% | 640,900 | +16.0% | 0.00% | +200.0% |
| Q1 2018 | $3,985,000 | +131.8% | 552,665 | +18.3% | 0.00% | – |
| Q4 2017 | $1,719,000 | +0.3% | 467,048 | +18.0% | 0.00% | – |
| Q3 2017 | $1,714,000 | +211.1% | 395,802 | +16.3% | 0.00% | – |
| Q2 2017 | $551,000 | -19.6% | 340,297 | -8.1% | 0.00% | – |
| Q1 2017 | $685,000 | -48.0% | 370,303 | -56.5% | 0.00% | – |
| Q4 2016 | $1,318,000 | -87.2% | 850,385 | -39.5% | 0.00% | -100.0% |
| Q3 2016 | $10,330,000 | +117.3% | 1,405,492 | +57.3% | 0.00% | +100.0% |
| Q2 2016 | $4,754,000 | – | 893,527 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,264 | $54,392,000 | 33.22% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $216,228,000 | 28.00% |
| L1 Capital Pty Ltd | 296,024 | $19,629,000 | 4.93% |
| Aquilo Capital Management, LLC | 407,926 | $27,050,000 | 4.89% |
| Evolutionary Tree Capital Management, LLC | 72,948 | $4,837,000 | 2.86% |
| ACUTA CAPITAL PARTNERS, LLC | 108,000 | $7,161,000 | 2.58% |
| First Light Asset Management, LLC | 536,836 | $35,598,000 | 2.36% |
| Parkman Healthcare Partners LLC | 70,089 | $4,648,000 | 1.08% |
| Hood River Capital Management LLC | 357,082 | $23,678,000 | 0.76% |
| Vanguard Capital Wealth Advisors | 11,099 | $703,565,000 | 0.60% |